MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study

Approximately 25% of melanoma patients with locoregional metastases are nonresponsive to new molecular target therapy and immunotherapy. When metastases are located in the pelvis, melphalan hypoxic perfusion can be an optional treatment. Because methylation of MGMT promoter increases the efficacy of...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Melanoma Res
Hlavní autoři: Guadagni, Stefano, Fiorentini, Giammaria, Clementi, Marco, Palumbo, Giancarlo, Masedu, Francesco, Deraco, Marcello, De Manzoni, Giovanni, Chiominto, Alessandro, Valenti, Marco, Pellegrini, Cristina
Médium: Artigo
Jazyk:Inglês
Vydáno: Lippincott Williams & Wilkins 2017
Témata:
ORIGINAL ARTICLES: Translational research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5592983/
https://ncbi.nlm.nih.gov/pubmed/28486243
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CMR.0000000000000367
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky